IVIG in APS pregnancy

Lupus

Volumn 13, Issue 9, 2004, Pages 731-735

  Triolo, G ^a,b   Ferrante, A ^a   Accardo Palumbo, A ^a   Ciccia, F ^a   Cadelo, M ^a   Castelli, A ^a   Perino, A ^a   Licata, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Divisione Medicina Interna e Specialistica   (Italy)

Author keywords

APS; IVIG; Pregnancy; Recurrent fetal loss

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; IMMUNOGLOBULIN G; PREDNISONE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG MEGADOSE; FETUS DISTRESS; HUMAN; IMMUNOMODULATION; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; NONHUMAN; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOSIS;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 4644288625     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2011oa     Document Type: Conference Paper

References (85)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-489.
2. Alarcón-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-365
3. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
4. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
5. Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-272.
6. De Groot PG, Horbach DA, Derksen RHWM. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996; 5: 488-493.
7. Mori T, Takeya H, Nishioka H, Gabazza EC, Suzuki K. β-glycoprotein I modulates the anticoagulant activity 2 of protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-55.
8. Oosting JD, Preissner KT, Derksen RHWM, De Groot PG. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993; 85: 761-768.
9. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-724.
10. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anticardiolipin antibodies. J Immunol 1994; 153: 1328-1332.
11. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-841.
12. Dobado-Barrios PM, Lopez-Pedrera C, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 1578-1582.
13. Reverter JC, Tassies D, Font J et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16: 1319-1326.
14. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41: 179.
15. De Wolf F, Carreras LO, Moerman P et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thrombombolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829.
16. Ogishima D, Matsumoto T, Nakamura Y et al. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies. Pathol Int 2000; 50: 224.
17. Fishman P, Falach-Vaknine E, Zigelman R et al. Prevention of fetal loss in experimental anti-phospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91: 1834.
18. Katsuragawa H, Rote NS, Inoue T et al. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gynecol 1995; 172: 1592.
19. Holers VM, Girardi G, Mo, L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211.
20. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069.
21. Branch DW, Dudley DJ, Mitchell MD et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210.
22. Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA 1993; 90: 6464.
23. Rand JH, Wu XX, Guller S et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566.
24. Rand JH, Wu XX, Guller S et al. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177: 918.
25. Rand JH, Wu XX, Andree HA et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154.
26. Krikun G, Lockwood CJ, Wu XX et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation. Placenta 1994; 15: 601.
27. Rand JH, Wu XX, Andree HA et al. Pregnancy loss in the antiphospholipid-antibody syndrome A possible thrombogenic mechanism. N Engl J Med 1997; 337: 154.
28. Romisch J, Schorlemmer U, Fickenscher K et al. Anticoagulant properties of placenta protein 4 (Annexin V). Thromb Res 1990; 60: 355.
29. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944.
30. Gris JC, Perneger TV, Quere I et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003; 102: 3504.
31. Geha RS, Rosen FS. Intravenous immunoglobulin therapy. In Austen KF, Burakoff SJ, Rosen FS, Strom TB eds. Therapeutic immunology. Cambridge, MA: Blackwell Science, 1996: 280-296.
32. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-234.
33. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia: competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; 2: 193-195.
34. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody. N Engl J Med 1986; 314: 1236-1239.
35. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945-949.
36. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
37. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721-730.
38. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-1735.
39. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-193.
40. Andersson U, Bjork L, Skansen SU, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
41. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-216.
42. Ruiz de Souza V, Carreno MP, Kaveri SV et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25: 1267-1273.
43. Arend WP, Smith MF Jr, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1βproduction in human monocytes are regulated differently. J Immunol 1991; 147: 1530-1536.
44. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.V. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999; 52: 1833-1838.
45. Xu C, Poirier B, Van Huyen JP et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 1998; 153: 1257-1266.
46. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 602-607.
47. Baudet V, Hurez V, Lapeyre C, Kaveri SV, Kazatchkine MD. Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro. Scand J Immunol 1996; 43: 277-282.
48. Leung DY. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996; 104(Suppl 1): 49-54.
49. Sundblad A, Marcos M, Malanchere E et al. Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev 1994; 139: 125-158.
50. Spinnato JA, Clark AL, Pierangeli E, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome hi pregnancy. Am J Obstet Gynecol 1995; 172: 690-694.
51. Scott JR, Branch DR, Kochenour NK, Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 1988; 159: 1055-1056.
52. Abedi MR, Hammarstrom L, Broome U, Angelin B, Smith CI, Christensson B. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin Exp Immunol 1996; 105: 266-273.
53. Galli D, Vaccaio F, Ferri GM et al. Anti-Idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic uses. J Autoimmun 1994; 7: 537-548.
54. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83: 298-303.
55. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-316.
56. Saoudi A, Hurez V, de Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5: 1559-1567.
57. Pashov A, Kaveri S, Kazatchkine MD, Bellon B. Suppression of experimental autoimmune encephalomyelitis by intravenous immunoglobulin. In Kazatchkine MD, Morell A eds. Intravenous immunoglobulin: research and therapy. New York: Parthenon Publishing, 1996: 317-318.
58. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89: 3325-3329.
59. Prasad NK, Papoff G, Zeuner A et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781-3790.
60. Sell S, Fahey JL. Relationship between g-globulin metabolism and low serum γ-globulin in germfree mice. J Immunol 1964; 93: 81-87.
61. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683-689.
62. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996; 93: 5512-5516.
63. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18: 592-598.
64. Galli M, Cortellazzo S, Barbui T. In vivo efficacy of intravenous immunoglobulins in patient with lupus anticoagulanti is not mediated by anti-idiotypic mechanism. Am J Hematol 1991; 38: 184-188.
65. Said PB, Martinuzzo ME, Carreras LO. Neutralization of lupus anticoagulant activity by human immunoglobulin 'in vitro'. Nouv Ref Fr Hematol 1992; 34: 37-42.
66. Pierangeli SS, Espinola R, Xiaowei L, Harris EN, Salmon JE. Identification of an Fcγ receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 2001; 44: 876-883.
67. Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996; 14 (Suppl 15): S9-S15.
68. Karlsson MC, Wernersson S, Diaz de Ståhl T, Gustavsson S, Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fcgreceptor-deficient mice. Proc Natl Acad Sci USA 1999; 96: 2244-2249.
69. Bakimer R, Guilburd B, Zugil N, Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69: 97-102.
70. Krause I, Blank M, Kopolovic J. et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 22: 1068-1074.
71. Carreras LO, Perez GN, Vega HR, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 1988; 2: 393-394.
72. Parke A, Maier D, Wilson D et al. Intravenous gamma-globulin, anti-phospholipid antibodies and pregnancy. Ann Intern Med 1989; 110: 495-496.
73. Wapner RJ, Cowchock FSm Shapiro SS. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous gamma globulin infusions. Am J Obstet Gynecol 1989; 616: 1271-1272.
74. Ron-el R, Vinder A, Golan A et al. The use of intravenous gammaglobulin, heparin and aspirin in the mainteinance of pregnancy of freeze thawed embryo in a patient with lupus-like anticoagulant. Eur J Obstet Gynecol Reprod Biol 1993; 52: 131-133.
75. Kaaja R, Julkunen H, Ammala P, Palosuo T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scandinavica 1993; 72: 63-66.
76. Valensise H, Vaquero E, De Carolis C et al. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose of intravenous immunoglobulin (IVIG). Prenatal Diag 1995; 15: 509-517.
77. Clark AL, Branch DW, Silver RM, Harris EN, Pierangeli S, Spinnato JA. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999; 93: 437-441.
78. Marzusch K, Dietl J, Klein R, Hornung D, Neuer A, Berg PA, Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scandinavica 1996; 75: 922-926.
79. Kwak JY, Quilty EA, Gilman-Sachs A, Beaman KD, Beer AE. Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologies. J Reprod Immunol 1995; 28: 175-188.
80. Branch DW, Peaceman AM, Druzin M et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182: 122-127.
81. Vaquero E, Lazzarin N, Valensise H et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low dose aspirin. Am J Reprod Immunol 2001; 45: 174-179.
82. Triolo G, Ferrante A, Ciccia F et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728-731.
83. di Simone N, de Carolis S, Lanzone A et al. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotrophin releasing hormone-dependent human chorionic gonadotrophin release by cultured trophoblast cells. Placenta 1995; 16: 75.
84. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211.
85. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to b2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352: 1037-1038.